Redeye provides its first take on Camurus’ Q3 report 2025, published this morning. Sales of Buvidal and Brixadi were both lower than we had projected, although Brixadi grew by 25% Q/Q. Buvidal had its second sequential sales decline. Operating costs were lower, resulting in a strong EBIT margin. Overall, the report falls short of our expectations.
